Core Viewpoint - The approval of the innovative drug Sotatercept for temporary importation in China represents a significant advancement in the treatment of pulmonary arterial hypertension (PAH), a rare and life-threatening vascular disease [1] Group 1: Drug Approval and Characteristics - Sotatercept is the world's first and only activin signaling pathway inhibitor specifically for the treatment of arterial pulmonary hypertension [1] - The drug has received several designations, including breakthrough therapy and orphan drug status in the U.S., as well as priority medicine and orphan drug status in the EU [1] - Regulatory approvals from the U.S. Food and Drug Administration and the European Medicines Agency are expected in March and August 2024, respectively [1] Group 2: Disease Context and Need for Treatment - Pulmonary arterial hypertension is characterized by narrowing of the pulmonary arteries due to vascular remodeling, leading to increased pulmonary artery pressure and resistance [1] - Without timely and effective treatment, the condition can progress to right heart failure and become life-threatening [1] - Research indicates that from 2010 to 2019, the one-year and three-year survival rates for PAH patients have not significantly improved, with a five-year mortality rate of 40% for newly diagnosed patients, highlighting the urgent need for innovative treatment options to improve quality of life and prognosis [1]